Novartis Financial Ratios
NYSE: NVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Novartis ratio analysis
Return on equity reached 30.3%, meaning Novartis generated 0.30 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.03 versus 0.09 the year before, and the current ratio was 1.12. At the end of FY 2025, NVS traded at 19.4 times earnings; across the 10 fiscal years shown, its year-end P/E ranged from 8.2 to 28.6, with a median of 19.1.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Novartis financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 19.38 | 16.63 | 14.22 | 28.62 | 8.23 | 26.83 | 18.73 | 14.31 | 23.15 | 23.31 |
| Price / book | 5.82 | 4.47 | 4.49 | 3.33 | 2.90 | 3.80 | 3.91 | 2.27 | 2.38 | 2.07 |
| Return on equity (ROE) | 30.3% | 27.1% | 31.8% | 11.7% | 35.5% | 14.3% | 21.1% | 16.0% | 10.4% | 9.0% |
| Return on assets (ROA) | 12.6% | 11.7% | 14.9% | 5.9% | 18.2% | 6.3% | 9.9% | 8.7% | 5.8% | — |
| Debt / equity | 0.03 | 0.09 | 0.06 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | 0.01 | — |
| Current ratio | 1.12 | 1.04 | 1.16 | 1.29 | 1.51 | 0.90 | 1.04 | 1.20 | 1.21 | — |
| EPS growth | 21.8% | -17.3% | 124.0% | -70.2% | 202.0% | -30.4% | -5.9% | 65.5% | 16.1% | — |